Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
entrez:
9
11
2022
pubmed:
10
11
2022
medline:
11
11
2022
Statut:
ppublish
Résumé
Prevalence of heart failure is increasing worldwide mainly due to the ageing of the population and the improvement in diagnosis and treatment. In recent years, huge progress has been made in the management of heart failure patients. A new definition of chronic heart failure based on left ventricular ejection fraction and its possible trajectories has been reported. New drug classes have been introduced for the treatment of chronic heart failure. In particular, the prognostic benefit of sodium glucose co-transporter 2 inhibitors was demonstrated across all the heart failure phenotypes. Therapies for patients with advanced heart failure (long-term mechanical circulatory supports and heart transplantation) are now indicated also in the case of mild-to-moderate symptoms but with high risk of progression. In patients with acute heart failure, monitoring of urinary sodium and the use of acetazolamide may lead to better decongestion. Importantly, pre- and postdischarge assessment should lead to optimal treatment. Devices and telemonitoring can also be of help. Cardiovascular and noncardiovascular comorbidities are major determinants of the clinical course and need proper management. This review will summarize these important advances.
Identifiants
pubmed: 36349941
doi: 10.2459/JCM.0000000000001409
pii: 01244665-202212000-00001
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Symporters
0
Glucose
IY9XDZ35W2
Sodium
9NEZ333N27
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
761-769Informations de copyright
Copyright © 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22:1342–1356.
Seferovic PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinkovic I, et al. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021; 23:906–914.
Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, et al. A year in heart failure: an update of recent findings. ESC Heart Fail 2021; 8:4370–4393.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599–3726.
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021; 23:352–380.
Seferovic PM, Jankowska E, Coats AJS, Maggioni AP, Lopatin Y, Milinkovic I, et al. The Heart Failure Association Atlas: rationale, objectives, and methods. Eur J Heart Fail 2020; 22:638–645.
Russo G, Rea F, Barbati G, Cherubini A, Stellato K, Scagnetto A, et al. Sex-related differences in chronic heart failure: a community-based study. J Cardiovasc Med (Hagerstown) 2021; 22:36–44.
Suthahar N, Meems LMG, Ho JE, de Boer RA. Sex-related differences in contemporary biomarkers for heart failure: a review. Eur J Heart Fail 2020; 22:775–788.
Ravera A, Santema BT, de Boer RA, Anker SD, Samani NJ, Lang CC, et al. Distinct pathophysiological pathways in women and men with heart failure. Eur J Heart Fail 2022.
Lainscak M, Milinkovic I, Polovina M, Crespo-Leiro MG, Lund LH, Anker SD, et al. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020; 22:92–102.
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21:715–731.
Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 2020; 22:350–361.
Kuan WS, Ibrahim I, Chan SP, Li Z, Liew OW, Frampton C, et al. Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation. Eur J Heart Fail 2020; 22:692–700.
Carubelli V, Lombardi C, Lazzarini V, Bonadei I, Castrini AI, Gorga E, et al. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. J Cardiovasc Med (Hagerstown) 2016; 17:828–839.
Chioncel O, Collins SP, Greene SJ, Ambrosy AP, Vaduganathan M, Macarie C, et al. Natriuretic peptide-guided management in heart failure. J Cardiovasc Med (Hagerstown) 2016; 17:556–568.
Lubrano V, Vergaro G, Maltinti M, Ghionzoli N, Emdin M, Papa A. alpha-1 Antitrypsin as a potential biomarker in chronic heart failure. J Cardiovasc Med (Hagerstown) 2020; 21:209–215.
Georgiopoulos G, Aimo A, Barison A, Magkas N, Emdin M, Masci PG. Imaging predictors of incident heart failure: a systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2021; 22:378–387.
Bosso G, Valvano A, Guarnaccia F, Fimiani B, Carbone V, Cittadini A, et al. Adherence to guidelines in the management of patients with chronic heart failure follow-up: role of periodic echocardiographic examinations. J Cardiovasc Med (Hagerstown) 2020; 21:216–222.
Seferovic PM, Tsutsui H, McNamara DM, Ristic AD, Basso C, Bozkurt B, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 2021; 23:854–871.
Peretto G, Cappelletti AM, Spoladore R, Slavich M, Rizzo S, Palmisano A, et al. Right ventricular endomyocardial biopsy in patients with cardiac magnetic resonance showing left ventricular myocarditis. J Cardiovasc Med (Hagerstown) 2021; 22:560–566.
Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, et al. Viral presence-guided immunomodulation in lymphocytic myocarditis: an update. Eur J Heart Fail 2021; 23:211–216.
Merlo M, Mase M, Cannata A, Zaffalon D, Lardieri G, Limongelli G, et al. Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology. J Cardiovasc Med (Hagerstown) 2020; 21:927–943.
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail 2020; 22:228–240.
Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 2020; 22:1076–1096.
de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets: a position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail 2022; 24:406–420.
Merlo M, Cannata A, Pio Loco C, Stolfo D, Barbati G, Artico J, et al. Contemporary survival trends and aetiological characterization in nonischaemic dilated cardiomyopathy. Eur J Heart Fail 2020; 22:1111–1121.
Porcu M, Corda M, Pasqualucci D, Binaghi G, Sanna N, Matta G, et al. A very long-term observation of a family with dilated cardiomyopathy and overlapping phenotype from lamin A/C mutation. J Cardiovasc Med (Hagerstown) 2021; 22:53–58.
Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail 2019; 6:1105–1127.
Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail 2020.
Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? Eur Heart J Cardiovasc Pharmacother 2021; 7:539–546.
Sciatti E, Senni M, Lombardi CM, Gori M, Metra M. Sacubitril/valsartan: from a large clinical trial to clinical practice. J Cardiovasc Med (Hagerstown) 2018; 19:473–479.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
Chen X, Schaufelberger M, Fu M. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016. J Cardiovasc Med (Hagerstown) 2020; 21:6–12.
Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani MP, et al. Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail 2021; 8:3547–3556.
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 2019; 73:2365–2383.
Vader JM, Givertz MM, Starling RC, McNulty SE, Anstrom KJ, Desvigne-Nickens P, et al. Tolerability of sacubitril/valsartan in patients with advanced heart failure: analysis of the LIFE Trial Run-In. JACC Heart Fail 2022; 10:449–456.
Mapelli M, Salvioni E, de Martino F, Mattavelli I, Bonomi A, Sassi V, et al. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2020; 21:882–888.
Valentim Goncalves A, Galrinho A, Pereira-da-Silva T, Branco L, Rio P, Timoteo AT, et al. Myocardial work improvement after sacubitril–valsartan therapy: a new echocardiographic parameter for a new treatment. J Cardiovasc Med (Hagerstown) 2020; 21:223–230.
Villani A, Ravaro S, Cerea P, Caravita S, Ciambellotti F, Branzi G, et al. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration? J Cardiovasc Med (Hagerstown) 2020; 21:682–687.
Dereli S, Bayramoglu A, Kaya A. Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2020; 21:13–20.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413–1424.
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995–2008.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385:1451–1461.
Anker SD, Siddiqi TJ, Filippatos G, Zannad F, Ferreira JP, Pocock SJ, et al. Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions. Eur J Heart Fail 2022; 24:1400–1405.
Boorsma EM, Beusekamp JC, Ter Maaten JM, Figarska SM, Danser AHJ, van Veldhuisen DJ, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail 2021; 23:68–78.
Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020; 22:713–722.
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 2021; 23:1217–1225.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022.
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2022; 24:431–441.
Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2022; 80:1302–1310.
Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022; 28:1956–1964.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail 2020; 8:329–340.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020; 382:1883–1893.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e895–e1032.
Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F, et al. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 2022; 9:1507–1523.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. J Am Coll Cardiol 2021; 78:97–108.
Straw S, McGinlay M, Gierula J, Lowry JE, Paton MF, Cole C, et al. Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. J Cardiovasc Med (Hagerstown) 2021; 22:848–856.
Santangelo G, Bursi F, Negroni MS, Gentile D, Provenzale G, Turriziani L, et al. Arrhythmic event prediction in patients with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2021; 22:110–117.
Masini M, Elia E, Vianello PF, Bertero G, Rossi P, Ameri P, et al. Frequency, predictors and prognostic impact of implantable cardioverter defibrillator shocks in a primary prevention population with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2021; 22:118–125.
Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care – a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail 2020; 22:2349–2369.
Kuschyk J, Falk P, Demming T, Marx O, Morley D, Rao I, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system. Eur J Heart Fail 2021; 23:1160–1169.
Linde C, Grabowski M, Ponikowski P, Rao I, Stagg A, Tschope C. Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM-HFpEF). Eur J Heart Fail 2022; doi: 10.1002/ejhf.2619. Online ahead of print.
doi: 10.1002/ejhf.2619.
Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021; 398:991–1001.
Palmisano P, Melissano D, Zanotto G, Perego GB, Toselli T, Landolina M, et al. Change in the use of remote monitoring of cardiac implantable electronic devices in Italian clinical practice over a 5-year period: results of two surveys promoted by the AIAC (Italian Association of Arrhythmology and Cardiac Pacing). J Cardiovasc Med (Hagerstown) 2020; 21:305–314.
Tersalvi G, Vicenzi M, Kirsch K, Gunold H, Thiele H, Lombardi F, et al. Structured telephone support programs in chronic heart failure may be affected by a learning curve. J Cardiovasc Med (Hagerstown) 2020; 21:231–237.
Pagnesi M, Lombardi CM, Chiarito M, Stolfo D, Baldetti L, Loiacono F, et al. Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry. Eur J Heart Fail 2022; 24:1493–1503.
Bianco F, Bucciarelli V, Ammirati E, Occhi L, Musca F, Tonti G, et al. Assessment of right ventricular function in advanced heart failure with nonischemic dilated cardiomyopathy: insights of right ventricular elastance. J Cardiovasc Med (Hagerstown) 2020; 21:134–143.
Vishram-Nielsen JKK, Tomasoni D, Gustafsson F, Metra M. Contemporary drug treatment of advanced heart failure with reduced ejection fraction. Drugs 2022; 82:375–405.
Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. Eur J Heart Fail 2020; 22:2340–2346.
Lombardi CM, Cimino G, Pellicori P, Bonelli A, Inciardi RM, Pagnesi M, et al. Congestion in patients with advanced heart failure: assessment and treatment. Heart Fail Clin 2021; 17:575–586.
Lilliu M, Onorati F, Luciani GB, Faggian G. The determinants of functional capacity in left ventricular assist device patients: many actors with not well defined roles. J Cardiovasc Med (Hagerstown) 2020; 21:472–480.
Karason K, Lund LH, Dalen M, Bjorklund E, Grinnemo K, Braun O, et al. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. Eur J Heart Fail 2020; 22:739–750.
Sponga S, Nagpal AD, Vendramin I, Ferrara V, Lechiancole A, Maiani M, et al. Bridge to heart transplantation in patients with cardiogenic shock: a 20-year experience with two different surgical strategies. J Cardiovasc Med (Hagerstown) 2021; 22:388–395.
Gupta AK, Tomasoni D, Sidhu K, Metra M, Ezekowitz JA. Evidence-based management of acute heart failure. Can J Cardiol 2021; 37:621–631.
Tomasoni D, Lombardi CM, Sbolli M, Cotter G, Metra M. Acute heart failure: more questions than answers. Prog Cardiovasc Dis 2020; 63:599–606.
Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2019; 21:1338–1352.
Iacovoni A, Palmieri V, Abete R, Vecchi AL, Mortara A, Gori M, et al. Right and left ventricular structures and functions in acute HFpEF: comparing the hypertensive pulmonary edema and worsening heart failure phenotypes. J Cardiovasc Med (Hagerstown) 2022; 23:663–671.
Lombardi C, Peveri G, Cani D, Latta F, Bonelli A, Tomasoni D, et al. In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Fail 2020; 7:2650–2661.
Pugliese NR, Fabiani I, Conte L, Nesti L, Masi S, Natali A, et al. Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study. J Cardiovasc Med (Hagerstown) 2020; 21:494–502.
Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen HK, et al. Clinical importance of urinary sodium excretion in acute heart failure. Eur J Heart Fail 2020; 22:1438–1447.
Biegus J, Zymlinski R, Testani J, Marciniak D, Zdanowicz A, Jankowska EA, et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur J Heart Fail 2021; 23:729–739.
Cunha FM, Pereira J, Marques P, Ribeiro A, Bettencourt P, Lourenco P. Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. J Cardiovasc Med (Hagerstown) 2020; 21:21–26.
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022; 387:1185–1195.
Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, et al. Extracorporeal ultrafiltration for fluid overload in heart failure: current status and prospects for further research. J Am Coll Cardiol 2017; 69:2428–2445.
Carubelli V, Lombardi C, Specchia C, Peveri G, Oriecuia C, Tomasoni D, et al. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure. ESC Heart Fail 2021; 8:1944–1953.
Rosano GMC, Vitale C, Adamo M, Metra M. Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. J Cardiovasc Med (Hagerstown) 2022; 23:149–156.
Cheng CW, Liu MH, Wang CH. Predictors of infection-related rehospitalization in heart failure patients and its impact on long-term survival. J Cardiovasc Med (Hagerstown) 2020; 21:889–896.
Casebeer A, Horter L, Hayden J, Simmons J, Evers T. Phenotypic clustering of heart failure with preserved ejection fraction reveals different rates of hospitalization. J Cardiovasc Med (Hagerstown) 2021; 22:45–52.
Gliozzi M, Scarano F, Musolino V, Carresi C, Scarcella A, Nucera S, et al. Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy. J Cardiovasc Med (Hagerstown) 2021; 22:268–278.
Siegel RM, Ostfeld RJ, Aboodi MS, Vittorio TJ, Mehlman Y, Travin MI. Relationship between extreme obesity and mortality in patients with reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2021; 22:279–284.
Metra M, Jankowska EA, Pagnesi M, Anker SD, Butler J, Dorigotti F, et al. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial. Eur J Heart Fail 2022; doi: 10.1002/ejhf.2630. Online ahead of print.
doi: 10.1002/ejhf.2630.
Li L, Liu R, Jiang C, Du X, Huffman MD, Lam CSP, et al. Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. Eur J Heart Fail 2020; 22:646–660.
Lombardi CM, Carubelli V, Peveri G, Inciardi RM, Pagnesi M, Ravera A, et al. Prognostic significance of serum potassium in patients hospitalized for acute heart failure. ESC Heart Fail 2022; 9:2357–2366.
Butler J, Khan MS, Friede T, Jankowska EA, Fabien V, Goehring UM, et al. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. Eur J Heart Fail 2022; 24:821–832.
Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020; 396:1895–1904.
McEwan P, Ponikowski P, Davis JA, Rosano G, Coats AJS, Dorigotti F, et al. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF. Eur J Heart Fail 2021; 23:1687–1697.
Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlstrom U, et al. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail 2021; 23:1844–1854.
Ullah W, Al-Khadra Y, Mir T, Darmoch F, Pacha HM, Sattar Y, et al. Temporal trends in utilization and outcomes of transcatheter aortic valve replacement in different races: an analysis of the national inpatient sample. J Cardiovasc Med (Hagerstown) 2021; 22:586–593.
Coats AJS, Anker SD, Baumbach A, Alfieri O, von Bardeleben RS, Bauersachs J, et al. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J 2021; 42:1254–1269.
Zaccone G, Di Pasquale M, Fiorina C, Curello S, Metra M, Adamo M. Transcatheter therapies for tricuspid valve regurgitation. J Cardiovasc Med (Hagerstown) 2020; 21:964–974.
Russo M, Zilberszac R, Werner P, Kocher A, Wiedemann D, Schneider M, et al. Isolated tricuspid valve regurgitation: old concepts, new insights and innovation. J Cardiovasc Med (Hagerstown) 2020; 21:406–414.
Zuin M, Rigatelli G, Ronco F. Worldwide and European interest in the MitraClip: a Google Trends-based analysis. J Cardiovasc Med (Hagerstown) 2020; 21:246–249.
Giannini C, D’Ascenzo F, Fiorelli F, Spontoni P, Swaans MJ, Velazquez EJ, et al. A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. ESC Heart Fail 2018; 5:1150–1158.
Godino C, Scotti A, Taramasso M, Adamo M, Russo M, Chiarito M, et al. Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and nonischemic dilated cardiomyopathy. Int J Cardiol 2018; 269:33–39.
Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail 2021; 23:1750–1758.
Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clin Res Cardiol 2022; 111:912–923.
Higuchi S, Orban M, Adamo M, Giannini C, Melica B, Karam N, et al. Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation. Eur J Heart Fail 2022; doi: 10.1002/ejhf.2613. Online ahead of print.
doi: 10.1002/ejhf.2613.
Iliadis C, Kalbacher D, Lurz P, Petrescu AM, Orban M, Puscas T, et al. Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation. Eur J Heart Fail 2022; 24:1282–1292.
Iliadis C, Baldus S, Kalbacher D, Boekstegers P, Schillinger W, Ouarrak T, et al. Impact of left atrial diameter on outcome in patients undergoing edge-to-edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) registry. Eur J Heart Fail 2020; 22:1202–1210.
Caiffa T, De Luca A, Biagini E, Lupi L, Bedogni F, Castrichini M, et al. Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation. Eur J Heart Fail 2021; 23:1765–1774.
Tamargo M, Obokata M, Reddy YNV, Pislaru SV, Lin G, Egbe AC, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail 2020; 22:489–498.
Doldi P, Stolz L, Orban M, Karam N, Praz F, Kalbacher D, et al. Transcatheter mitral valve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc Imaging 2022; S1936-878X(22)00343-6.
Popolo Rubbio A, Testa L, Grasso C, Sisinni A, Tusa M, Agricola E, et al. Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from the multicenter MITRA-TUNE registry. Int J Cardiol 2022; 349:39–45.
Messika-Zeitoun D, Verta P, Gregson J, Pocock SJ, Boero I, Feldman TE, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. Eur J Heart Fail 2020; 22:1803–1813.
Kresoja KP, Lauten A, Orban M, Rommel KP, Alushi B, Besler C, et al. Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. Eur J Heart Fail 2020; 22:1817–1825.
Besler C, Unterhuber M, Rommel KP, Unger E, Hartung P, von Roeder M, et al. Nutritional status in tricuspid regurgitation: implications of transcatheter repair. Eur J Heart Fail 2020; 22:1826–1836.
Fogarassy G, Vathy-Fogarassy A, Kenessey I, Veress G, Polgar C, Forster T. Preventing cancer therapy-related heart failure: the need for novel studies. J Cardiovasc Med (Hagerstown) 2021; 22:459–468.
Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; ehac244. doi: 10.1093/eurheartj/ehac244. Online ahead of print.
doi: 10.1093/eurheartj/ehac244.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2021; 23:512–526.
Tomasoni D, Aimo A, Merlo M, Nardi M, Adamo M, Bellicini MG, et al. Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis. Eur J Heart Fail 2022; doi: 10.1002/ejhf.2616. Online ahead of print.
doi: 10.1002/ejhf.2616.
Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020; 22:391–412.
Gospodinova M, Sarafov S, Chamova T, Kirov A, Todorov T, Nakov R, et al. Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation. J Cardiovasc Med (Hagerstown) 2020; 21:688–695.
Di Nora C, Sponga S, Ferrara V, Patriarca F, Fanin R, Nalli C, et al. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation. J Cardiovasc Med (Hagerstown) 2021; 22:261–267.